在收购Damora Therapeutics后,Galecto Inc.的幅达到了29%,获得了针对罕见血液癌症的抗体计划,并获得了到2029年之前的资金. Galecto Inc. surged 290% after acquiring Damora Therapeutics, gaining antibody programs for rare blood cancers and securing funding to reach 2029.

随着公司收购Damora Therapeutics,Galecto Inc.股价升超过290%至19.40美元,获得了针对突变性卡尔雷蒂库林引起的罕见血液癌症的三项抗体计划,包括精髓血栓细胞血症和骨髓纤维化. Galecto Inc. shares jumped over 290% to $19.40 as the company acquired Damora Therapeutics, gaining three antibody programs targeting rare blood cancers caused by mutant calreticulin, including essential thrombocythemia and myelofibrosis. 这笔交易得到了2849万美元的C轮融资支持,扩大了Galecto的财务运行路径到2029年,并支持即将到来的临床里程碑,包括2026年中期的DMR-001的IND提交,这是一个有前途的抗mutCALR疗法,以及预期的2026年第一季度的GB3226的IND提交,这是一种用于治疗急性髓性白血病的双重向药物. The deal, backed by a $284.9 million Series C funding round, extends Galecto’s financial runway through 2029 and supports upcoming clinical milestones, including a mid-2026 IND submission for DMR-001, a promising anti-mutCALR therapy, and an anticipated Q1 2026 IND filing for GB3226, a dual-targeting drug for acute myeloid leukemia.